GINA ORTIZ: Open Payments
NPI 1942480462 · BERLIN, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,328 in 76 payments from 20 companies in 2025. Trend: 2023 $1,955 · 2024 $2,045 · 2025 $1,328
Food & beverage: $1,328
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $253 |
| ABBVIE INC. | 13 | $159 |
| Novo Nordisk Inc | 9 | $151 |
| Otsuka America Pharmaceutical, Inc. | 8 | $142 |
| Lilly USA, LLC | 6 | $101 |
| Antares Pharma, Inc. | 4 | $78 |
| PFIZER INC. | 4 | $69 |
| Lundbeck LLC | 3 | $54 |
| Amgen Inc. | 3 | $52 |
| Madrigal Pharmaceuticals | 3 | $50 |
Products named: REXULTI, AIRSUPRA, MOUNJARO, Wegovy, UBRELVY, XYOSTED, EVENITY, REZDIFFRA.
Industry payments across NJ — which companies pay providers there.
